On a preliminary basis, Integra LifeSciences (NASDAQ:IART) sees Q4 revenues at or near the bottom of its previously announced range of $395M – 400M.
Preliminary 2020 guidance: Revenues: $1.55B – 1.57B (+3%); EPS growth: double-digit.
The company plans to implement a share repurchase program authorized to buy back up to $225M of its common stock.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.